a new report that provides in-depth analysis of leading pharma companies that are using novel technologies to reposition failed, marketed or reformulated compounds.

Analysis of Genentech’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

The Merck & Co Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Genzyme Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

High impact company profile available at BioMarket

Overview of adjuvants for prophylactic vaccines with detailed profiles and critical assessment of key products. Discussion of the regulatory environment with strategic recommendations for adjuvant developers to optimize chances of market approval.

Iomai Corporation: Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

The report "Asia Pacific Biotechnology Market (2007-2010)" provides an updated and detailed overview of the Asia-Pacific Biotechnology industry.

This analysis examines the historical and forecast performance for Biogen Idec in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year

This analysis examines the historical and forecast performance for Watson in the generic pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sale

This report provides an overview of the pharmaceutical distribution model in Europe and the US, and highlights recent changes in the supply chain that impact on the industry, particularly with regards to parallel trade and counterfeit strategies.

This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of vaginal infections drugs by company and by stage as well as a summary of the latest news and developments in this area.

Parkinson’s disease (PD) is a progressive, degenerative condition of the central nervous system that affects the way the brain coordinates body movements, including walking, talking and writing. PD affects less than 1% of the population in the se

High impact company profile available at BioMarket

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of hypogonadism drugs by company and by stage as well as a summary of the latest news and developments in this area.

The UI market is set to continue to grow over the next 6 years, reaching over $2.5 billion in 2012, a 68% increase from 2006. Lifecycle management strategies, novel formulations and follow-on products will drive the majority of this growth, with key br

Global Cancer Focus Company Directory pulls out virtually all drug developing companies in oncology in the world. After several acquisitions and mergers, BioSeeker offers you the tool to get an updated look on the competitive landscape in oncology, inc

Orexigen Therapeutics Inc: Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

The aim of this study is to provide in depth information on the developing market for genomics products and services.

High impact company profile available at BioMarket

The Bigpharma Dealmaking Handbook 2007 provides an in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies

The current perception is that new drugs rely on old delivery technologies to get past the regulatory authorities, whereas old drugs look to new techniques to survive.<(p>

Danaher is a diversified technology company engaged in designing, manufacturing and marketing of professional, medical, industrial and consumer products with strong brand names and significant market positions.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of bronchospasm drugs by company and by stage as well as a summary of the latest news and developments in this area.

In 2006 visiongain valued this market at $37406m, But do you know how the blood diseases treatments market will fare 5, 10 and 15 years from now?

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders. With a forecast incidence of 36,769 across the seven major markets in 2007, they are one of the most common hematological malignancies. Currently, the only

Analysis of Roche’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

This report provides comprehensive coverage of the major markets in the global cancer area, incorporating a detailed epidemiological analysis of the nine major indications and key factors impacting their prevalence.